coronavirus infectious disease Open Targets releases our COVID-19 Target Prioritisation Tool Open Targets is excited to introduce our COVID-19 Target Prioritisation Tool - http://covid19.opentargets.org/ - an interactive web portal allows users to explore host and viral targets and potential COVID-19 treatments
release notes Open Targets Platform 20.06 has been released! We have a new release of the Open Targets Platform with new disease terms including COVID-19, new chemical probes, updates to Open Targets Genetics evidence and more.
release notes Open Targets Platform 20.04 has been released! We have a new release of the Open Targets Platform with new target safety data, new target tractability modalities, more chemical probes and new associations.
Q&A Prioritising your list of potential drug targets with tractability assessments How tractable is a drug target? In this Open Targets Q&A, we explore the ChEMBL tractability (druggability) pipeline implemented in the Open Targets Platform.
Open Targets Genetics GWAS causal inference in Open Targets Finding GWAS causal inference for target identification and prioritisation using Open Targets Genetics and the Open Targets Platform.
Q&A Special Q&A with Gosia Trynka, Open Targets Experimental Science director We're delighted to have caught up with Gosia Trynka, our new Experimental Science director, for a very special Q&A on Open Targets science and more.
release notes Open Targets Platform: release 20.02 is out We have a new release of the Open Targets Platform with a brand new data source, Open Targets Genetics Portal, more chemical probes and new intOGen data.
Cancer An Open Targets Away Day with The Institute of Cancer Research Open Targets meets colleagues at the Institute of Cancer Research in London: potential collaboration ahead of us.
Q&A Getting to know intOGen, a resource for the identification of cancer driver genes Open Targets Q&A on identifying cancer driver genes and their mechanism of action with intOGen.
ontology EFO3: A community-driven ontology to advance clinical discoveries In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.
release notes Open Targets Platform: release 19.11 is out We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.
A-Z From antibody to zinc finger: an A-Z of Open Targets As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.
release notes Open Targets Platform: release 19.09 is out We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.
A-Z From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
release notes Open Targets Platform: release 19.06 is out We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.
release notes Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
Q&A Avoiding confusion in disease biology with ontologies Open Targets Q&A on the importance of describing diseases with ontologies when searching for new therapeutic targets in drug discovery.
A-Z From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. March is time for E.
release notes Open Targets Platform: release 19.02 is out Our latest release of the Open Targets Platform is out. We have more targets, more diseases, more evidence, more associations, and fixed some bugs too.
